Dylan A Levy, Jaimin J Patel, Shaun A Nguyen, W Nicholas Jungbauer, David M Neskey, Ezra E W Cohen, Chrystal M Paulos, John A Kaczmar, Hannah M Knochelmann, Terry A Day
{"title":"头颈部鳞状细胞癌中的程序性死亡 1 (PD-1) 和配体 (PD-L1) 抑制剂：一项荟萃分析。","authors":"Dylan A Levy, Jaimin J Patel, Shaun A Nguyen, W Nicholas Jungbauer, David M Neskey, Ezra E W Cohen, Chrystal M Paulos, John A Kaczmar, Hannah M Knochelmann, Terry A Day","doi":"10.1002/wjo2.15","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).</p><p><strong>Methods: </strong>Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).</p><p><strong>Results: </strong>Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19, <i>P</i> < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.</p><p><strong>Conclusions: </strong>Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted.</p>","PeriodicalId":32097,"journal":{"name":"World Journal of OtorhinolaryngologyHead and Neck Surgery","volume":"8 3","pages":"177-186"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/a7/WJO2-8-177.PMC9479482.pdf","citationCount":"0","resultStr":"{\"title\":\"Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis.\",\"authors\":\"Dylan A Levy, Jaimin J Patel, Shaun A Nguyen, W Nicholas Jungbauer, David M Neskey, Ezra E W Cohen, Chrystal M Paulos, John A Kaczmar, Hannah M Knochelmann, Terry A Day\",\"doi\":\"10.1002/wjo2.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).</p><p><strong>Methods: </strong>Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).</p><p><strong>Results: </strong>Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19, <i>P</i> < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.</p><p><strong>Conclusions: </strong>Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted.</p>\",\"PeriodicalId\":32097,\"journal\":{\"name\":\"World Journal of OtorhinolaryngologyHead and Neck Surgery\",\"volume\":\"8 3\",\"pages\":\"177-186\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/a7/WJO2-8-177.PMC9479482.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of OtorhinolaryngologyHead and Neck Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/wjo2.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of OtorhinolaryngologyHead and Neck Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/wjo2.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景PD-1和PD-L1抑制剂已成为治疗头颈部鳞状细胞癌（HNSCC）患者的有效方法：方法：对PD-1和PD-L1抑制剂在HNSCC中的应用进行系统回顾和荟萃分析。结果：中位总生存期（mOS）、中位无进展生存期（mPFS）、实体瘤反应评价标准（RECIST）和治疗相关不良事件（TRAEs）：11项试验报告了1088名患者的数据（平均年龄59.9岁，范围18-90岁）。总生存期为 7.97 个月（范围：6.0-16.5）。所有研究的平均 mPFS 为 2.84 个月（范围：1.9-6.5）。与PD-L1抑制剂相比，PD-1抑制剂的RECIST进展期病变率较低（42.61%，95%置信区间[CI]：36.29-49.06 vs. PD-L1抑制剂）：36.29-49.06 vs. 56.79%，95% 置信区间 [CI]：49.18-64.19，P 结论：Meta分析表明了PD-1和PD-L1抑制剂在HNSCC中的疗效，并提示PD-1和PD-L1抑制剂在某些RECIST标准上可能存在差异。未来有必要研究这些发现的临床意义。
Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis.
Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).
Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).
Results: Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19, P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.
Conclusions: Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
